Crispr Therapeutics AG (CRSP) Stock Price & Analysis

11,095 Followers

CRSP Stock Chart & Stats

$48.56-$3.21(-6.21%)

At close: Nov 05 4:00 PM EST

Day’s Range: $47.76 - $51.21
52-Week Range: $44.12 - $63.45
Previous Close: $51.78
Volume: N/A
Average Volume (3M): 1.45M
Market Cap: $5.02B
Enterprise Value: $3.86B
Total Cash (Recent Filing): $2.27B
Total Debt (Recent Filing): $779.83M
Price to Earnings (P/E): ―
Beta: 1.87
Next Earnings: Feb 16, 2027 (Est.)
EPS Estimate: -1.17
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

CRISPR Platform And Pipeline

A focused CRISPR/Cas9 platform applied across multiple therapeutic areas gives CRISPR Therapeutics several development opportunities rather than reliance on one indication. The breadth of its ex vivo and other gene-editing approaches may support durable pipeline optionality as clinical programs advance.

Revenue Rebound

The sharp TTM revenue rebound indicates that collaboration or product-related economics can improve materially when programs reach relevant milestones or commercial stages. Although revenue remains uneven, this growth provides evidence of monetization potential within the company’s development model.

Equity Balance-sheet Support

A sizable equity base provides financial cushioning while the company funds expensive gene-editing research and clinical development. This support can help preserve strategic flexibility and sustain investment in the pipeline, even though ongoing losses continue to consume capital.

Bears Say

Persistent Operating Losses

Large operating and net losses show that the current business remains far from self-funding and depends on future clinical, regulatory, or commercial progress to improve earnings. Continued negative margins could constrain investment capacity and weaken financial resilience if losses persist.

Sustained Cash Burn

Material operating and free-cash-flow outflows demonstrate that reported losses are translating into real cash consumption. Persistent burn increases the importance of available funding and future capital access, while reducing the company’s ability to finance development solely from internally generated cash.

Volatile Collaboration-driven Revenue

Reliance on collaborations and milestone-linked economics makes revenue timing dependent on scientific, clinical, regulatory, and commercial thresholds. This can create uneven results and limited earnings visibility, complicating long-term planning and making durable profitability harder to establish.

Crispr Therapeutics AG News

Crispr Therapeutics Updates CTX131 Cancer Trial: What Investors Need to Know

Crispr Therapeutics ($CRSP) announced an update on their ongoing clinical study. Study Overview: Crispr Therapeutics’ official study title is “A Phase 1/2 Dose Evaluation and Cohort Expansion Study of the

18h agoCRSP

Crispr Therapeutics price target lowered to $80 from $81 at BofA

BofA analyst Alec Stranahan lowered the firm’s price target on Crispr Therapeutics (CRSP) to $80 from $81 and keeps a Buy rating on the shares. Published first on TheFly –

1d agoCRSP 1CG

Crispr Therapeutics price target raised to $90 from $88 at Citi

Citi raised the firm’s price target on Crispr Therapeutics (CRSP) to $90 from $88 and keeps a Buy rating on the shares post the Q3 report. The firm says the

1d agoCRSP 1CG

Crispr Therapeutics price target lowered to $70 from $75 at Wells Fargo

Wells Fargo lowered the firm’s price target on Crispr Therapeutics (CRSP) to $70 from $75 and keeps an Equal Weight rating on the shares. The firm notes CASGEVY revenue grew

1d agoCRSP VRTX

CRISPR Therapeutics’ Growing Casgevy Adoption and Near-Term Pipeline Catalysts Support a Buy Rating

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on CRSP stock, giving a Buy rating today. Brian Cheng’s rating is based on several factors supporting CRISPR Therapeutics AG’s

2d agoCRSP 1CG

Crispr Therapeutics reports Q3 EPS ($1.15), consensus ($1.00)

Reports Q3 revenue $12.669M, consensus $16.56M. “The third quarter marked meaningful progress for CRISPR Therapeutics (CRSP),” said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. “CASGEVY is

3d agoCRSP 1CG

Crispr Therapeutics appoints Sivakesava Sakhamuri as chief technical officer

Crispr announced the appointment of Sivakesava Sakhamuri as chief technical officer, effective immediately. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA

3d agoCRSP 1CG

Crispr Therapeutics Expands Into Autoimmune Neurology With New CTX112 Trial

Crispr Therapeutics ($CRSP) announced an update on their ongoing clinical study. Crispr Therapeutics (CRSP) has launched a new early-stage study called “A Phase 1/2 Dose Evaluation Trial of the Safety

2w agoCRSP

CRISPR Therapeutics Appoints Andrew Silver as New CFO

Crispr Therapeutics AG ( ($CRSP) ) just unveiled an announcement. On October 19, 2026, CRISPR Therapeutics AG promoted Andrew J. Silver, previously Senior Vice President of Finance, to Chief Financial

2w ago8K CRSP

Crispr Therapeutics CFO Raju Prasad to step down, A.J. Silver to succeed

Crispr Therapeutics (CRSP) announced that its CFO, Raju Prasad will be stepping down from the company to pursue external opportunities, and A.J. Silver, the company’s senior VP of finance, will

2w agoCRSP 1CG

Amprius, Viking, Regeneron, Ionis, Crispr Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($AMPX) ), ( ($VKTX) ), ( ($REGN) ), ( ($IONS) ) and ( ($CRSP) ). Here is a breakdown of their recent

2w agoAMPX CRSP

Crispr Therapeutics management to meet with Piper Sandler

Meeting to be held in Boston on October 15 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See

3w agoCRSP 1CG

Crispr Therapeutics initiated with a Neutral at UBS

UBS initiated coverage of Crispr Therapeutics (CRSP) with a Neutral rating and $52 price target The company’s validated genome editing platform is a historic first with an approved cell therapy,

3w agoCRSP 1CG

Cathie Wood Just Sold $3.36M in META Stock. Here’s What She Bought Instead

On Monday, Cathie Wood’s ARK Invest sold 4,520 shares of Meta Platforms ($META) through its ARK Innovation ETF ($ARKK). Based on Meta’s closing price of $742.96, the sale was worth

3w agoGH ALMR

CRSP FAQ

What was Crispr Therapeutics AG’s price range in the past 12 months?

Crispr Therapeutics AG lowest stock price was $44.12 and its highest was $63.45 in the past 12 months.

What is Crispr Therapeutics AG’s market cap?

Crispr Therapeutics AG’s market cap is $5.02B.

When is Crispr Therapeutics AG’s upcoming earnings report date?

Crispr Therapeutics AG’s next earnings report is estimated for Feb 16, 2027 (not yet confirmed), which is in 102 days.

How were Crispr Therapeutics AG’s earnings last quarter?

Crispr Therapeutics AG released its earnings results on Nov 02, 2026. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.037 by -$0.113.

Is Crispr Therapeutics AG overvalued?

According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.

Does Crispr Therapeutics AG pay dividends?

Crispr Therapeutics AG does not currently pay dividends.

What is Crispr Therapeutics AG’s EPS estimate?

Crispr Therapeutics AG’s EPS estimate is -1.17.

How many shares outstanding does Crispr Therapeutics AG have?

Crispr Therapeutics AG has 97,000,820 shares outstanding.

What happened to Crispr Therapeutics AG’s price movement after its last earnings report?

Crispr Therapeutics AG reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.037. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Crispr Therapeutics AG?

Hedge funds hold Crispr Therapeutics AG shares: the largest hedge-fund position in Crispr Therapeutics AG is 70,139,053 shares, and hedge funds decreased their holdings by 1.0M shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Crispr Therapeutics AG Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Crispr Therapeutics AG

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.

Crispr Therapeutics AG (CRSP) Earnings & Revenues

Historic Earnings Reports

CRSP Stock 12 Month Forecast

Average Price Target

$70.83▲(45.87% Upside)

Past 12 Months12 Month ForecastFeb2026Nov2026

High$110.00

Average$70.83

Low$45.00

Detailed Analyst Forecast >

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	2	5	15
Technical Analysis	2	5	3
Moving Averages	0	0	12

Technical Analysis >

Similar Stocks

Stocks similar to CRSP
Company	Price & Change	Follow
NTLAIntellia Therapeutics
BEAMBeam Therapeutics
LEGNLegend Biotech
KYMRKymera Therapeutics

Compare CRSP Stocks >

Ownership Overview

2.61% Insiders
13.70% Mutual Funds
2.72% Other Institutional Investors
60.66% Public Companies and Individual Investors

Detailed Ownership Overview >

Options Prices

Expiration Date: Nov 6, 2026

CallsPuts

CRSP call options for the Nov 6, 2026 expiration
Last Price	% Change	Strike
―	―	47.0
―	―	48.0
―	―	49.0
―	―	50.0
―	―	51.0
―	―	52.0

CRSP put options for the Nov 6, 2026 expiration
Last Price	% Change
―	―
―	―
―	―
―	―
―	―
―	―

Detailed Option Prices >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft